Home » 2. Meeting the Challenge

2. Meeting the Challenge


Clive Badman OBE

Formerly VP and Head of Pre-Competitive Activities for GSK

Project Director, ReMediES


We set out to do two things in particular in ReMediES. The first was to shorten the length of the supply chain from up to two years to about six months. The second was to increase the quality of manufacturing to make it ‘right first time’. Along the way, we were determined to play our part of keeping the UK on the global medicines advanced manufacturing and supply map.


Companies and organisations, both big and small, were able to make significant strides by being part of ReMediES, for instance in testing, trialling and bringing new equipment to market: both technologies that are already proving themselves such as continuous direct compression, and others such as hot melt extrusion, that offer huge opportunities for rapid entry into clinical trials.


ReMediES helped bring a facility that uses supercritical fluid engineering to control particle size back to the UK from China, boosting the UK’s capacity. Just-In-Time automated pharmacy, developed as part of the clinical supply chain workstream, now offers a huge opportunity to reduce waste and increase speed in clinical trials, promising an important role in commercial supply chains for precision medicines. The enzymes work under ReMediES attracted significant interest and has, I think, started something big. We moved forwards in packaging, with some great work done on labels that help track products through GPS, and tell you what temperature and humidity they experienced along the way. And perhaps the unsung hero has been the work to demonstrate the potential of digital manufacturing. This, together with digital design and digital supply chain, offers huge opportunity for medicines supply chains in the future


I can’t say that we have achieved six months cycle time, but we have moved towards that. In the coming years, I believe we will be seen to have helped our industry across the tipping point on continuous manufacturing, with continuous, or a hybrid of batch and continuous, becoming commonplace, bringing better Right-First-Time outcomes.


In the coming pages, we present an insight into the different workstreams: what they achieved and what they will now make possible.